Ryan D. Cassaday

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Also affiliated with University of Washington, Fred Hutch Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma”.

Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023011287

N/A

1.7DataRank · unranked

55 citations

Erik L. Kimble, Jocelyn H. Wright, Salvatore Fiorenza, Jordan Gauthier, Jenna Voutsinas +18 more

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

The Lancet Haematology(2021)10.1016/s2352-3026(21)00170-8

N/A

1.6DataRank · unranked

59 citations

Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren +15 more

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

Blood Advances(2023)10.1182/bloodadvances.2023011399

N/A

0.958DataRank · unranked

34 citations

Aya Albittar, Jennifer J. Huang, Alexandre V. Hirayama, Erik L. Kimble, Andrew J. Portuguese +11 more

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Blood Advances(2025)10.1182/bloodadvances.2024015314

N/A

0.447DataRank · unranked

10 citations

Emily C. Liang, Jennifer J. Huang, Erik L. Kimble, Alexandre V. Hirayama, Salvatore Fiorenza +15 more

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7561

N/A

0DataRank · unranked

1 citations

Jonathan R. Fromm, Min Fang, Brian G. Till, Mazyar Shadman, Andrew J. Cowan +11 more

Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7511

N/A

0DataRank · unranked

1 citations

Alexandre V. Hirayama, Erik L. Kimble, Andrew J. Portuguese, Aya Albittar, Aude G. Chapuis +8 more

A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7007

N/A

0DataRank · unranked

1 citations

Kim Quach, Ted Gooley, Christen H. Martino, Sindhu Cherian, Mary‐Elizabeth M. Percival +8 more

Development and validation of predictive models of early immune effector cell–associated hematotoxicity

Blood Advances(2024)10.1182/bloodadvances.2024014455

N/A

0DataRank · unranked

10 citations

Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz‐Maldonado, Aya Albittar, Natalie Wuliji +28 more

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.10.002

N/A

0DataRank · unranked

12 citations

Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan +10 more

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Blood Advances(2021)10.1182/bloodadvances.2021004916

N/A

0DataRank · unranked

77 citations

Leland Metheny, Mei‐Jie Zhang, Hailin Wang, Noel Estrada‐Merly, David I. Marks +72 more

Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad306

N/A

0DataRank · unranked

13 citations

Leah H Yoke, Pooja Bhattacharyya, Ryan D. Cassaday, Guang‐Shing Cheng, Zahra Kassamali Escobar +8 more

A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab (Anti‐CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma

American Journal of Hematology(2020)10.1002/ajh.25818

N/A

0DataRank · unranked

10 citations

Joseph G. Rajendran, Darrell R. Fisher, Frederick R. Appelbaum, Ryan D. Cassaday, Paul S. Martin +8 more